Family · Pharmaceutical analytical standards
Cariprazine
An atypical antipsychotic that acts as a partial agonist at dopamine D3 and D2 receptors, with a preference for D3; approved in the United States in 2015 and in Europe in 2017 for schizophrenia, and in the United States also for bipolar disorder. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It was discovered in Hungary, where it was known by the code RGH-188; its active metabolites stay in the body for one to three weeks, far longer than the parent molecule.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
